Nine Years of Omeprazole and No Reason Left: A Pharmacology-Based Plan to Deprescribe a Proton Pump Inhibitor in a 68-Year-Old Woman
[Student Name]
University of Phoenix
NSG/522: Advanced Pharmacology
Week 4 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. No real patient is described.
A composite 68-year-old retired dental office manager had taken omeprazole 40 mg daily for nine years. It was started during a stressful year when she had nightly heartburn and was never stopped. At a medication review, she said her heartburn had been gone for years, but she worried it would return. She had never had an endoscopy, gastrointestinal bleeding or a peptic ulcer, and she took no nonsteroidal anti-inflammatory drugs, aspirin or anticoagulants. Recent laboratory tests showed a serum magnesium of 1.6 mg/dL, slightly below normal, and a borderline vitamin B12 level, and her bone density scan showed osteopenia. The pill had outlasted the problem it was prescribed for by most of a decade, and no one had asked whether it still belonged on her list. This paper explains the pharmacology behind deciding whether, and how, to stop it.
How Proton Pump Inhibitors Work
Proton pump inhibitors (PPIs) act on the last step of acid production. Parietal cells pump hydrogen ions into the stomach in exchange for potassium, using an ATPase that sits in the membrane of their secretory canaliculi. PPIs are weakly basic prodrugs that accumulate in that acidic space, are converted there to their active sulfenamide form and bond covalently to cysteine residues of the pump, disabling it permanently. Acid output recovers only as the cell synthesizes new pumps.
Two practical points follow from this mechanism. First, PPIs work best when taken 30 to 60 minutes before the first meal of the day, when food stimulates the largest number of pumps to become active and thus available for inhibition. Second, because inhibition is irreversible, the effect lasts longer than the drug stays in the blood, and full effect takes several days of regular dosing.
Why Stopping Can Cause Rebound
Long-term acid suppression removes the normal feedback by which stomach acid inhibits gastrin release. Gastrin rises and stimulates enterochromaffin-like cells to release histamine and to proliferate, and it promotes growth of the parietal cell mass. When the PPI is stopped abruptly, the enlarged acid-producing capacity is suddenly unopposed, and acid secretion can rise above pretreatment levels for weeks, a phenomenon called rebound acid hypersecretion. Even people who never had reflux can develop heartburn after stopping a PPI they took for several weeks. Patients often interpret this rebound as proof that they still need the drug.
Weighing Long-Term Harms Honestly
Long-term PPI use has been associated in observational studies with many adverse outcomes, including kidney disease, fractures, dementia, pneumonia, Clostridioides difficile infection, vitamin B12 deficiency and low magnesium. Freedberg et al. (2017), in an expert review for the American Gastroenterological Association, concluded that the quality of evidence for most of these associations is low, that many may reflect confounding because sicker people are more likely to take PPIs, and that the decision to continue a PPI should be based on whether it is indicated rather than on fear of harms. They advised that patients with a definite indication should continue, and that patients without one should be considered for stopping.
Some harms are better supported mechanistically. Low stomach acid impairs release of vitamin B12 from food proteins, and long-term PPI use can reduce intestinal magnesium absorption through effects on transient receptor potential channels. This patient's low magnesium and borderline B12 are consistent with those mechanisms, which adds a reason to reconsider the drug.
Does She Still Have an Indication?
The American Gastroenterological Association's update on deprescribing recommends that every patient taking a PPI have the indication reviewed and that those without a definitive indication be considered for trial discontinuation (Targownik et al., 2022). Definitive indications include Barrett's esophagus, severe erosive esophagitis, a history of bleeding peptic ulcer and gastroprotection for people at high risk of bleeding, such as those on dual antiplatelet therapy or anticoagulants with other risk factors.
This patient has none of these. Her PPI was started for heartburn during a stressful period, her symptoms resolved long ago and she takes no drugs that would require gastroprotection. She is a candidate for deprescribing.
The Deprescribing Plan
The plan uses the mechanism of rebound to reduce it. Omeprazole is reduced from 40 mg to 20 mg daily for four weeks, then stopped. During and after the taper, she may use famotidine, a histamine H2 receptor antagonist, as needed for occasional heartburn; H2 blockers act faster than PPIs, do not produce the same degree of rebound and are appropriate for intermittent symptoms. If symptoms recur and persist beyond the expected rebound period of several weeks, on-demand PPI use at the lowest effective dose is an option. Boghossian et al. (2017), in a Cochrane review of deprescribing studies, found that switching to on-demand use reduced pill burden but was associated with a higher chance of symptoms returning than continuous use, so the plan was framed as a trial with clear follow-up rather than a promise that symptoms would never recur.
Nonpharmacologic measures support the plan: avoiding large late meals, raising the head of the bed if nighttime symptoms return and limiting known triggers. Her magnesium was rechecked four weeks after stopping, her B12 was repeated with a methylmalonic acid level and her calcium and vitamin D intake were reviewed for bone health.
Why the Prescription Persisted
The nine-year course of this prescription is common, and understanding why helps prevent it. PPIs are often started during hospital stays or for short-term symptoms without a documented stop date, and later clinicians see a long-standing medication and assume it has a reason. Patients who try stopping abruptly experience rebound heartburn and conclude they need the drug. Over-the-counter availability makes the drug seem harmless. The nurse practitioner therefore documented the indication review, the taper plan and the planned reassessment in the record and in a letter to the patient, so that a future clinician seeing omeprazole, or its absence, would understand the decision.
Teaching
The nurse practitioner explained that some heartburn in the first few weeks after stopping is expected and usually temporary, reflecting the stomach's adjustment rather than a return of disease. She asked the patient to call at once for trouble swallowing, repeated vomiting, dark tarry stools, unplanned weight loss or chest pain, since these alarm features would require evaluation rather than simply restarting the PPI. A follow-up call was scheduled at four weeks and a visit at three months.
Conclusion
A proton pump inhibitor started for temporary heartburn became a nine-year prescription in a woman with no continuing indication and two laboratory findings consistent with its known effects. Understanding how PPIs irreversibly inhibit the proton pump, why long-term suppression raises gastrin and why abrupt withdrawal causes rebound acid hypersecretion allowed the nurse practitioner to taper the drug, provide an H2 blocker for breakthrough symptoms, weigh the evidence on harms honestly and monitor for recurrence. Deprescribing is prescribing in reverse, and it requires the same pharmacologic reasoning.
References
Boghossian, T. A., Rashid, F. J., Thompson, W., Welch, V., Moayyedi, P., Rojas-Fernandez, C., Pottie, K., & Farrell, B. (2017). Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database of Systematic Reviews, 2017(3), Article CD011969. https://doi.org/10.1002/14651858.CD011969.pub2
Freedberg, D. E., Kim, L. S., & Yang, Y.-X. (2017). The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology, 152(4), 706-715. https://doi.org/10.1053/j.gastro.2017.01.031
Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022). AGA clinical practice update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology, 162(4), 1334-1342. https://doi.org/10.1053/j.gastro.2021.12.247
How this NSG 522 Week 4 example is structured
The University of Phoenix library guide for NSG/522 lists Week 4 as Gastrointestinal, Renal, and GYN/GU Medications. The paper treats deprescribing as a pharmacology decision: the drug's mechanism explains both its benefit and the rebound that follows stopping it, and the evidence on harms is weighed honestly rather than overstated. The indication review comes before the plan, because a patient with a continuing indication should keep the drug, and the taper is built from the mechanism of rebound. Students search this week as NSG 522 Week 4, NSG522 Wk 4 or NSG/522 Wk 4; all three are the same assignment.
NSG/522 Week 4 questions, answered
What does NSG/522 Week 4 usually ask for?
The library guide for NSG/522 lists Week 4 as gastrointestinal, renal and gynecologic or genitourinary medications. Many sections ask for a paper or case analysis on prescribing or managing a drug from these classes, including mechanism, evidence and patient teaching.
Who should not stop a proton pump inhibitor?
Patients with a clear continuing indication, such as Barrett's esophagus, severe erosive esophagitis, a history of bleeding ulcer or ongoing use of drugs that raise bleeding risk, usually should continue. Deprescribing is meant for people who no longer have a clear reason to take the drug.
Why taper instead of stopping all at once?
Long-term acid suppression raises gastrin, which increases the acid-producing capacity of the stomach. Stopping suddenly can cause rebound acid hypersecretion and temporary heartburn even in people who never had reflux, which may lead them to restart the drug unnecessarily.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.